VEGFA and myocardial infarction: rSOST treatment resulted in increased transcription of VEGF-a, a master regulator of the hypoxic angiogenic response that targets cardiomyocytes, enhances EC survival, and increases capillary density at the site of myocardial infarction (Figure 6B) [58–60].